Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting

References

• Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the Functional Living Index-Emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 2006;4:35-41
   PubMedGoogle Scholar
• Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 2011;22:30-8
   PubMed Web of Science ®Google Scholar
• Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189-95
   PubMed Web of Science ®Google Scholar
• Haiderali A, Menditto L, Good M, et al. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Supportive Care Cancer 2011;19:843-51
   PubMed Web of Science ®Google Scholar
• Nevidjon B, Chaudhary R. Controlling emesis: evolving challenges, novel strategies. J Support Oncol 2010;8(4 Suppl 2):1-10
   PubMedGoogle Scholar
• Bouganim N, Dranitsaris G, Hopkins S, et al. Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. Curr Oncol 2012;19:e414-21
   PubMed Web of Science ®Google Scholar
• Hilarius DL, Kloeg PH, van der Wall E, et al. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 2012;20:107-17
   PubMed Web of Science ®Google Scholar
• Koch S, Wein A, Siebler J, et al. Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project. Support Care Cancer 2013;21:2395-402
   PubMed Web of Science ®Google Scholar
• Hori K, Kobayashi N, Atsumi H, et al. Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network. Support Care Cancer 2014;22:969-77
   PubMed Web of Science ®Google Scholar
• Gomez DR, Liao KP, Giordano S, et al. Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study. Cancer 2013;119:1428-36
   PubMed Web of Science ®Google Scholar
• Burmeister H, Aebi S, Studer C, et al. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 2012;20:141-7
   PubMed Web of Science ®Google Scholar
• Gilmore JW, Peacock NW, Gu A, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. J Oncol Pract 2012;10:68-74
   Google Scholar
• Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-8
   PubMed Web of Science ®Google Scholar
• Liau CT, Chu NM, Liu HE, et al. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes. Support Care Cancer 2005;13:277-86
   PubMed Web of Science ®Google Scholar
• Erazo Valle A, Wisniewski T, Figueroa Vadillo JI, et al. Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed. Curr Med Res Opin 2006;22:2403-10
   PubMed Web of Science ®Google Scholar
• Grunberg S. Patient-centered management of chemotherapy-induced nausea and vomiting. Cancer Contr 2012;19(2 Suppl):10-15
   PubMed Web of Science ®Google Scholar
• Salsman JM, Grunberg SM, Beaumont JL, et al. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Cancer Network 2012;10:149-57
   PubMed Web of Science ®Google Scholar
• Shih V, Wan HS, Chan A. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother 2009;43:444-52
   PubMed Web of Science ®Google Scholar
• Chan A, Low XH, Yap KY. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Managed Care Pharm 2012;18:385-94
   Google Scholar
• Celio L, Bonizzoni E, Bajetta E, et al. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Support Care Cancer 2013;21:565-73
   PubMed Web of Science ®Google Scholar
• Jin Y, Sun W, Gu D, et al. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis. Eur J Cancer Care 2013;22:41-50
   PubMed Web of Science ®Google Scholar
• Botrel TE, Clark OA, Clark L, et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 2011;19:823-32
   PubMed Web of Science ®Google Scholar
• Dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 2012;104:1280-92
   PubMed Web of Science ®Google Scholar
• Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 2012;684:1-7
   PubMed Web of Science ®Google Scholar
• Becker DE. Nausea, vomiting, and hiccups: a review of mechanisms and treatment. Anesth Prog 2010;57:150-6
   PubMedGoogle Scholar
• Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US Medicaid population with HIV. BMJ Open 2013;3
   Web of Science ®Google Scholar
• Hardinger KL, Hutcherson T, Preston D, et al. Influence of pill burden and drug cost on renal function after transplantation. Pharmacotherapy 2012;32:427-32
   PubMed Web of Science ®Google Scholar
• Balu S, Simko RJ, Quimbo RM, et al. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin 2009;25:2765-75
   PubMed Web of Science ®Google Scholar
• Craver C, Gayle J, Balu S, et al. Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 2011;14:87-98
   PubMedGoogle Scholar
• Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 2011;19:131-40
   PubMed Web of Science ®Google Scholar
• Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 2007;110:678-85
   PubMed Web of Science ®Google Scholar
• Lachaine J, Yelle L, Kaizer L, et al. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther 2005;2:181-7
   PubMedGoogle Scholar
• Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526-36
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, Barbour SY, Morrow GR, et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 2014;22:469-77
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Dugan M, Muss H, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009;17:589-94
   PubMed Web of Science ®Google Scholar
• Longo F, Mansueto G, Lapadula V, et al. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2011;19:1159-64
   PubMed Web of Science ®Google Scholar
• Calcagnile S, Lanzarotti C, Rossi G, et al. Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer 2013;21:2879-87
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014;25:1340-6
   PubMed Web of Science ®Google Scholar
• Aapro M, Rugo H, Rossi G, et al. A randomized phase 3 study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014;25:1328-33
   PubMed Web of Science ®Google Scholar
• Gralla R, Bosnjak S, Hontsa A, et al. A phase 3 study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 2014;25(7):1333-9
   PubMed Web of Science ®Google Scholar
• Avritscher EB, Shih YC, Sun CC, et al. Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. J Support Oncol 2010;8:242-51
   PubMedGoogle Scholar
• Annemans L, Strens D, Lox E, et al. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer 2008;16:905-15
   PubMed Web of Science ®Google Scholar
• Moore S, Tumeh J, Wojtanowski S, et al. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 2007;10:23-31
   PubMed Web of Science ®Google Scholar
• Lordick F, Ehlken B, Ihbe-Heffinger A, et al. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 2007;43:299-307
   PubMed Web of Science ®Google Scholar
• Breitscheidel L, Ehlken B, Kostev K, et al. Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany. J Med Econ 2012;15:155-65
   PubMedGoogle Scholar
• Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008;8:45-50
   PubMed Web of Science ®Google Scholar
• Fujii H, Iihara H, Ishihara M, et al. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk. Anticancer Res 2013;33:5549-56
   PubMed Web of Science ®Google Scholar
• Affronti ML, Schneider SM, Herndon JE 2nd, et al. Adherence to antiemetic guidelines in patients with malignant glioma: translating evidence into practice. Support Care Cancer 2014;22:1897-905
   PubMed Web of Science ®Google Scholar
• Liekweg A, Westfeld M, Braun M, et al. Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer 2012;20:2669-77
   PubMed Web of Science ®Google Scholar
• Trammel M, Roederer M, Patel J, et al. Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Curr Oncol Rep 2013;15:276-85
   PubMed Web of Science ®Google Scholar